Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA®

NCT01579695 is registered in ClinicalTrials.gov with Theratechnologies as lead sponsor.

NCT NCT01579695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01579695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA®
Lead sponsor
Theratechnologies
Phase
Observational
Overall status
Terminated
Start date
February 28, 2013
Completion date
August 31, 2018
Enrollment
391 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

hiv